Malignant Neoplasm of Unknown Primary — Trials

Malignant Neoplasm of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,158
Recruiting: 2,260
Ph III recruiting: 268
Growth YoY: +13.9%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,895)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02600949	Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer	enrolling by invitation	Phase 1	300	M.D. Anderson Cancer CenterOTHER	1	Jun 17, 2026	clinicaltrials
NCT07218003	A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4	enrolling by invitation	Phase 1	149	Rondo TherapeuticsINDUSTRY	1	Jun 11, 2026